The human immunodeficiency virus (HIV-1) has evolved into a viral quasispecies with a high replication capacity or fitness. Antiretroviral drugs potently inhibit replication of the wild-type virus, but HIV-1 responds by selection of drug-resistant variants. Here we review, in brief, the evolution of resistance to protease inhibitors that is characterized by severe fitness losses and an abundance of subsequent repair strategies. The possibility to restrict HIV-1 fitness is discussed in relation to the control of HIV-1 pathogenesis.
Introduction
Potent antiviraI drugs have been developed against HIV-1, targeting either the reverse transcriptase (RT) or the protease enzyme. But even in the context of the potent multidrug combination therapy now widely in use in some countries, the development of drug resistance remains a major problem in the treatment of HIV-1 infection and AIDS. The evolution of drug resistance has been analyzed both in patients and in tissue culture replication studies. For RT inhibitors, the picture that emerges is relatively simple, with one or a few amino acid substitutions in the RT enzyme that provide the drug-resistant phenotype. A more complex picture emerges in the evolution of resistance to protease inhibitors. The initial changes that provide resistance are observed in the protease gene, but there is continued evolution both in the protease gene and in secondary loci of the HIV-1 genome. This continued evolution is caused by the damaging side effects of the initial drug resistance mutations on protease enzyme function and virus replication. This loss of replication capacity or viral fitness is the driving force behind the subsequent cascade of adaptive changes. The multistep evolution of resistance to protease inhibitors will be described and contrasted with the relatively simple evolution of RT inhibitor resistance.
Fitness Loss in Drug-Resistant HIV-1
Fitness losses were first reported for HIV-1 variants with an amino acid substitution at position 184 within the catalytic core of the RT enzyme which provides resistance . Potymerase and other defects have been reported for this RT enzyme [27, 43, 55] and RT variants that are resistant to other drugs including zidovudine (AZT) [21, 23, 24, 42, 45] . More recently, impaired enzyme function and reduced viral fitness were reported for HIV-1 isolates with amino acid changes in the protease enzyme that provide resistance to protease inhibitors [12, 18, 25, 30, 38, 58] . The replication defects reported for protease-resistant viruses appear to be severer than the defects of RT-resistant viruses, which may in part explain the elaborate evolution pattern observed for the former variants. I will now provide an overview of the multistep evolution of protease resistance. In brief, the initial resistance mutations affect the enzyme function and proper processing of the viral Gag and Gag-Pol precursor proteins at one or several of the 9 cleavage sites ( fig. 1 ). Compensatory changes are observed at secondary sites within the protease enzyme, and mutations are selected at other loci of the HIV-1 genome, either to increase the expression of the malfunctioning protease enzyme or to modify the target-processing sites in the Gag and Gag-Pol precursor proteins.
Step-by-Step Evolution of Protease Inhibitor Resistance
Step 1: Potent Inhibition of the Wild-Type Virus
The HIV-1 quasispecies present in an infected individual occupies a narrow segment of total sequence space, which is illustrated in figure 2 as a peak of high fitness in the sequence landscape. Antiviral drugs interfere with replication of the wild-type virus, causing a severe loss of fitness. The potent antiviral effect forces HIV-1 to explore sequence space for variant genomes with improved viral replication properties or fitness. The virus can examine a number of alternative and disparate molecular pathways for correction of the genetic lesion and for fitness gain, but HIV-1 Evolution under Pressure of Protease Inhibitors: Climbing the Stairs of Viral Fitness J Biomed Sci 1999;6:298-305
